Novartis Kisqali significantly prolongs life in women with HR+/HER2- advanced breast cancer now in two distinct Phase III trials

    NEXT STORY
    Teladoc Health Reports Second Quarter 2019 Results
    PREV STORY
    BioRestorative Therapies Signs $5.4 Million Financing with Institutional Investor
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Chimerix Announces Exclusive Global License Agreement with SymBio Pharmaceuticals for Brincidofovir

    author_avatar
    NASDAQ Market News

    Health Needs Spike for Survivors of Indonesia’s Earthquake and Tsunami

    Millwood, VA, Oct. 06, 2018 (GLOBE NEWSWIRE) -- Project HOPE says serious health needs ...

    author_avatar
    NASDAQ Market News

    Pieris Pharmaceuticals to Present at 43rd Annual Deutsche Bank Health Care Conference

    BOSTON, May 03, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a biotechnology company advancing novel ...

    author_avatar
    NASDAQ Market News